Hypertriglyceridemia
Conditions
Keywords
n-3 LC-PUFA, hypertriglyceridemic, human, TAG
Brief summary
The study was performed to investigate the effects of a daily consumption of n-3 PUFA supplemented products (sausage, bread rolls, wafers, milk beverage) on cardiovascular risk factors in hypertriglyceridemic patients.
Detailed description
Recent studies suggest that n-3 LC-PUFA intake might be useful to prevent coronary heart diseases. As a precondition for participating in this study, the patients were provided information in writing and verbally about the details of the study. Written informed consent was obtained from all volunteers. Before the beginning of the study, all participants were subject to a medical examination by their general practitioners. Sixty hypertriglyceridemic patients (with triacylglyceride (TAG) values ≥ 150 mg/dl or ≥ 1.7 mmol/L) should entered the study. The placebo-controlled, randomized double-blind cross-over study consists of two investigation periods of 10 weeks, with a ten-week washout period in between. After the washout period the intervention was crossed between the groups and the respective products were consumed for another 10 weeks. Patients in the placebo period receive 60g sausage, 2 bread rolls (2x50g), 2 wafers and one bottle of the milk beverage daily. These products were enriched with sunflower oil (20g/d). In the intervention period, the products (60g sausage, 2 bread rolls (2x50g), 2 wafers and one bottle of the milk beverage) were enriched with a) 20g linseed oil, b) 20g echium oil, and c)12g microalgae powder. The daily dose of special n-3 fatty acid amounted to a) 10g alpha linolenic acid (ALA), b 2g stearidonic acid (SDA)+6g ALA, or c) 2g docosahexaenoic acid (DHA). Venous blood is collected at the beginning and at the end of each period.
Interventions
products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder 1. linseed oil (20g/d)(PPM, Magdeburg) 2. echium oil (20g/d) (HARKE Nutrition) 3. microalgae powder(12g/d)(HARKE Nutrition)
Sponsors
Study design
Eligibility
Inclusion criteria
* TAG values ≥ 150 mg/dl or ≥ 1.7 mmol/L
Exclusion criteria
* Lipid lowering medications * Glucocorticoids * Gastrointestinal or metabolic diseases (e.g., diabetes mellitus, hyperthyroidism or hypothyroidism, hypercholesteremic patients with familial previous impacts) * Daily alcohol abuse * Taking dietary supplements (e. g., fish oil capsules, vitamin E) * Known allergies or foodstuff indigestibility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood lipids (total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), TAG) | 10 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| high sensitive C-reactive protein | 10 weeks | — |
| oxidised LDL | 10 weeks | — |
| lipoprotein a | 10 weeks | Lipoprotein(a) |
| blood pressure | 10 weeks | — |
| intracellular adhesion molecule | 10 weeks | intracellular cell adhesion molecule |
| fatty acid distribution in plasma lipids and erythrocyte membranes | 10 weeks | — |
| vascular cell adhesion molecule | 10 weeks | vascular cell adhesion molecule |
Countries
Germany